by Barry101 | Aug 27, 2020 | Press Release, Uncategorized
OCALA, FL / August 27, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) is pleased to announce that it has identified an effective in vitro model at The Institute for Antiviral Research at Utah State University for testing Ampligen, a dsRNA TLR3 agonist, and the results...
by Barry101 | Aug 25, 2020 | Press Release, Uncategorized
OCALA, FL / August 25, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it will be presenting at The LD 500 Investor conference being held virtually on September 1-4, 2020. Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to...
by Barry101 | Aug 17, 2020 | Press Release, Uncategorized
Phase 1/2a trial of Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19 is on track for enrollment OCALA, FL / August 17, 2020 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of...
by Barry101 | Jul 27, 2020 | Press Release, Uncategorized
OCALA, FL / July 27, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it will be presenting at the SNN Network Virtual Investor Conference on Monday, August 3, 2020 at 1:30 PM EST. Thomas K. Equels, Chief Executive Officer of AIM Immunotech, will be...
by Barry101 | Jul 9, 2020 | Press Release, Uncategorized
Agreement Important Precursor to Next Step, Enrollment AIM is a Study Collaborator and Financial Supporter OCALA, FL / July 9, 2020 / AIM ImmunoTech (NYSE AMERICAN:AIM), today announced that it has entered into a clinical trial agreement (CTA) with Roswell Park...
by Barry101 | Jul 6, 2020 | Press Release, Uncategorized
OCALA, FL / July 6, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that is has signed a material transfer and research agreement with Japan’s National Institute of Infectious Diseases (NIID) and Shionogi & Co., Ltd. (Shionogi), a leading global...
